TZ10

Tirzepatide is a synthetic peptide designed as a dual agonist for both the GIP and GLP-1 receptors. This unique mechanism of action distinguishes it from traditional GLP-1 receptor agonists by leveraging the synergistic effects of both incretin hormones. In research settings, Tirzepatide is extensively studied for its potential in modulating glucose metabolism, promoting insulin secretion in a glucose-dependent manner, suppressing glucagon secretion, and delaying gastric emptying. Its multifaceted pharmacological profile makes it a key subject in investigations related to metabolic disorders, including type 2 diabetes, obesity, and associated cardiovascular risks. Researchers are exploring its impact on body weight reduction, glycemic control, and overall metabolic health. For optimal research integrity, Tirzepatide should be handled with care in a controlled laboratory environment. Researchers should wear appropriate personal protective equipment (PPE), including gloves, lab coats, and eye protection, to prevent direct contact. Avoid inhalation of powder or aerosols. Prepare solutions in a fume hood or well-ventilated area. After use, all waste materials should be disposed of according to institutional guidelines for chemical waste. To maintain its stability and biological activity, Tirzepatide should be stored under specific conditions. The lyophilized powder is best stored at -20°C or below, protected from light and moisture. Once reconstituted, solutions should be used promptly or stored refrigerated at 2-8°C for a short period (typically up to 7 days, depending on the solvent and concentration), or frozen at -20°C or below for longer-term storage. Repeated freeze-thaw cycles should be avoided as they can degrade the peptide. Always refer to the specific product's Certificate of Analysis for detailed storage and handling recommendations.